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ABSTRACT  
Introduction: 10% of corticotrophin (ACTH)-dependent Cushing’s syndrome arises from 
secretion by extra-pituitary tumors, with phaeochromocytoma implicated in a few cases. 
Ectopic secretion by phaeochromocytoma of corticotropin-releasing hormone (CRF), with 
secondary corticotroph hyperplasia, is even rarer, with only five cases in the literature 
hitherto. However, such cases may be classified as “ectopic ACTH” due to incomplete 
verification.  
Clinical cases: We describe three patients with phaeochromocytoma and ACTH-dependent 
Cushing’s syndrome in whom biochemical cure was achieved following unilateral 
adrenalectomy. Although unable to access a validated CRF assay within the timeframe for 
sample storage, we nevertheless inferred CRF secretion in 2/3 cases by tumor-
immunostaining (positive for CRF; negative for ACTH), supported in one case by pre-
operative inferior petrosal sinus sampling (IPSS) indicative of pituitary ACTH source. Both 
cases were characterized by rapid post-operative wean off glucocorticoids, presumed to 
reflect the pituitary stimulatory-effect of CRF outweighing central negative feedback-
inhibition by hypercortisolaemia. By contrast, the tumor excised in a third case exhibited 
positive immunostaining for ACTH -negative for CRF- and post-operative recovery of 
hypothalamo-pituitary-adrenal axis took significantly longer.  
Discussion: Ectopic CRF production is biochemically indistinguishable from ectopic ACTH 
secretion, except that IPSS mimics pituitary Cushing’s disease and cortisol dynamics may 
normalize rapidly post-adrenalectomy. CRF secretion can be inferred through tumor-
immunohistochemistry, even if no CRF assay is available. 
Unrecognized phaeochromocytoma ACTH-secretion may underpin some cases of 
cardiovascular collapse post-adrenalectomy through acute hypocortisolaemia.  
Despite advances in phaeochromocytoma genetics since previous reports, we were unable to 
identify somatic DNA defects associated with either ACTH- or CRF secretion. 
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INTRODUCTION 
Cushing’s syndrome has an estimated prevalence of approximately 40 per million and 
incidence of about 1-2 cases per million population per year [1]. It is conveniently classified 
as either ACTH-dependent or ACTH-independent Cushing’s syndrome. ACTH-dependent 
hypercortisolism accounts for about 85-90% of Cushing’s syndrome and is typically 
characterized by chronic autonomous ACTH secretion [2]. Pituitary ACTH-secreting 
corticotroph cell adenomas exist in virtually all patients with pituitary ACTH hypersecretion 
(Cushing’s disease), whereas diffuse hyperplasia of anterior pituitary corticotroph cells, 
potentially resulting from hypersecretion of CRF, occurs only rarely.  
Cushing’s syndrome has occasionally been attributed to concurrent ectopic secretion of both 
ACTH and CRF, but only rarely has it been unequivocally shown to be driven by 
autonomous ectopic CRF secretion, though incomplete biochemical and/or 
immunohistochemical characterization of published cases may partly explain this. Herein we 
present three patients with ACTH-dependent Cushing’s syndrome and phaeochromocytoma; 
in one cases the tumor autonomously secreted ACTH while, in the other two, it appeared to 
secrete CRF (or related peptide), which in turn drove abnormal pituitary ACTH dynamics and 
endogenous hypercortisolemia. In the case of primary ectopic ACTH secretion, normal 
cortisol dynamics following successful removal of the tumor was only achieved after a period 
of suppressed hypothalamic-pituitary-adrenal (HPA) axis due to previous hypercortisolemia. 
This was not the case with the ectopic CRF-driven Cushing’s, where normal cortisol 
dynamics were rapidly restored following successful tumor resection, without noticeable 
HPA axis suppression, in the immediate postoperative period. 
 
CLINICAL CASE REPORTS 
Case 1 
A 69 year-old female was admitted as a medical emergency with a two week history of 
oedema, uncontrolled hypertension and worsening hyperglycemia. Diabetes had been 
previously well-controlled with sub-maximal doses of metformin and gliclazide (HbA1c 
6.6%), but in the previous 12 months glycemic control had deteriorated despite stable 
lifestyle. Over the same period she also reported onset of episodic sweating, tremor and 
palpitations. Medical history included dyslipidemia, hypertension and controlled cardiac 
failure. She was borderline obese (weight 80.9 kg; BMI 30 kg/m2). She had a plethoric face 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
and exhibited cardiac decompensation, with bilateral edema to mid-thigh and blood pressure 
193/95 mmHg. ECG showed atrial fibrillation with fast ventricular response. Laboratory tests 
showed a markedly elevated plasma glucose 40.4 mmol/l, HbA1c 12.1% (NR <6.5%) and 
profound hypokalemia 1.9 mmol/l (NR 3.5-5.5).  
She received intravenous potassium, magnesium and amiodarone, via central venous catheter, 
followed by oral beta-blockade for rate control, but hypokalaemia was refractory to treatment 
until the addition of spironolactone. Very large doses of intravenous insulin were required to 
control plasma glucose, indicating marked insulin-resistance, and Cushing’s syndrome was 
thus suspected. However, she remained hypertensive and continued to have persistent 
palpitations, and thus suspicion of phaeochromocytoma also emerged. 
After eight days stabilization she was moved to the endocrine ward and investigated for 
evidence of cortisol and catecholamine excess. Overnight 1.5mg dexamethasone suppression 
test (ODST) showed an unsuppressed cortisol >2,000nmol/l (NR <50 nmol/l). Two 24 hour 
urine collections for urinary free cortisol (UFC) were also markedly elevated at 20,045 and 
15,625 nmol/l, respectively (NR 0-320); plasma ACTH 516 ng/l (NR<47) confirmed ACTH-
dependent hypercortisolism. ACTH precursors were elevated at 682 pmol/l [NR<40]. 
Phaeochromocytoma was also confirmed biochemically (Table 1), with fasting serum 
chromogranin A and pancreatic polypeptide both raised at 300 U/l [NR <30] and 710 ng/l 
[NR < 200]), respectively;  urine 5-HIAA was normal. 
MRI revealed no definite pituitary adenoma, but inferior petrosal sinus sampling (IPSS) 
nevertheless suggested pituitary Cushing’s disease without any clear lateralisation (Table 2). 
Cross-sectional imaging of the chest was normal, but the abdominal images showed a 3 cm 
right adrenal mass (with signal characteristics suggestive of phaeochromocytoma) and a 
bulky left adrenal gland consistent with chronically-raised ACTH drive (Figure 1). Meta-
iodobenzylguanidine (MIBG) scintigraphy showed no abnormal focus of uptake.  
Due to the severity of her illness she was started on Metyrapone for a total period of about 8 
weeks; the dose was titrated after 48–72 h based on cortisol day curve to 750mg thrice daily 
fortunately with rapid clinical and biochemical response -near-undetectable 24hr urine free 
cortisol (UFC)- and so was given add-back Dexamethasone replacement. After incremental 
alpha-blockade she underwent right adrenalectomy, following which her symptoms subsided, 
glycemic control improved and she was taken off insulin. Over a period of 10 weeks 
following adrenalectomy she was weaned-off glucocorticoid replacement and appeared to be 
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cured of both Cushing’s disease and phaeochromocytoma (Table 1). Histology confirmed 
phaeochromocytoma; subsequent immune-staining showed no reactivity for ACTH, but did 
show significant cytoplasmic granular labelling for CRF among a scattering of peripheral 
tumor cells.  
Six years post-adrenalectomy, she remains completely asymptomatic. In the intervening years 
she has undergone repair of an umbilical hernia and a second knee replacement; both of 
which were uneventful. Diabetes remains well controlled on just metformin 1 g twice daily 
and her blood pressure is maintained on perindopril 8 mg once daily. She remains under long 
term follow with the endocrine team. Although pre- and post-operative serum samples were 
stored for several years, we were unable to identify a laboratory with an “up-and-running” 
CRF assay during this period. Genetic analysis of lymphocyte DNA by UK national reference 
laboratory failed to show any coding sequence mutations in the PRKAR1A, SDHB, SDHC, 
SDHD, SDHAF2, TMEM127, VHL and MAX, or in exons 8, 10-11 and 13-16 of RET. MPLA 
analysis did not detect any evidence of a pathogenic deletion or duplication within SDHB, 
SDHC, SDHD, SDHAF2, or VHL. 
                                           
Case 2 
A 64-year old lady presented with abdominal pain and vomiting. She underwent an 
emergency laparotomy in which a metal wire impinging upon her small bowel (presumed 
from prior hysterectomy) was removed. Following this procedure her abdominal symptoms 
largely resolved, but review of the pre-operative CT of her abdomen also revealed an 
enhancing left adrenal mass and she was referred for endocrine assessment. She reported 
symptoms of non-specific tiredness and episodic sweating for the last 10 years, occasionally 
associated with palpitations. Her past medical history included treated hypertension and type 
2 diabetes mellitus. She had also received symptomatic treatment for presumed idiopathic 
hyperhidrosis in the past. Medication included metformin, lisinopril and simvastatin . Blood 
pressure was 162/75 mmHg with pulse 86/min.  
Initial investigations showed serum sodium 143 mmol/l (NR 135-145), potassium 4.5 mmol/l 
(NR 3.5-5.5) and HbA1c 6.5%. Cortisol was elevated at 9am (816 and 666 nmol/l) and 
midnight (175 nmol/l), as was ACTH (32 & 27 ng/l at 9am [NR<47] and 20 ng/l at 
midnight). Urine free cortisol was 47 nmols/24 hrs (NR <320), but 9am cortisol failed to 
suppress (<50 nmol/l) on dexamethasone suppression testing (DST): overnight 1mg (132 
nmol/L), two-day low-dose 0.5mg qds (187 nmol/l) and two-day high-dose 2g qds (312 
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nmol/l). Phaeochromocytoma was confirmed biochemically (Table 1), with raised 
catecholamine metabolites and chromogranin A (75 U/l [NR: <30]). MRI failed to 
demonstrate a pituitary lesion and MIBG scan showed uptake by the left adrenal gland.  
Following incremental oral alpha blockade she underwent left laparoscopic adrenalectomy, 
with resolution of symptomatology and biochemical cure of both phaeochromocytoma (Table 
1) and Cushing’s (Cortisol 102nmol/l at midnight and 33 nmol/l post-overnight 1mg DST). 
Blood pressure control improved, allowing antihypertensive drug doses to be halved. 
However, ACTH remained undetectable post-op and she required glucocorticoid replacement 
for six months thereafter.  
Sections of the adrenal gland showed a medullary tumor with histologic features of a 
phaeochromocytoma, containing scattered cells peripherally showing strong cytoplasmic 
granular labelling for ACTH, without significant labelling for CRF. Genetic analysis of 
lymphocyte DNA by UK national reference laboratory failed to show any variants in the 
SDHB, SDHD and VHL genes apart from common polymorphisms of no clinical significance 
and MPLA analysis did not detect any evidence of a pathogenic deletion or duplication 
within SDHB, SDHC, or SDHD genes.  
She remained under endocrine follow up for nearly 4 years, eventually dying of an unrelated 
cause. 
  
Case 3 
A 65 year old man with a history of benign prostatic hypertrophy presented to the emergency 
department of a private hospital in India with a history of vomiting, fever, rigors and 
anorexia. He was found to be febrile, dehydrated and emaciated, but was conscious and 
oriented with blood pressure 180/110mmHg. 
Initial laboratory tests showed hemoglobin 10.5 g/dl (NR 11-15), sodium 128 mmol/l (NR 
135-145), potassium 4.0 mmol/l (NR 3.5-5), glucose 220 mg/dl (NR <200mg/dL), urea 37 
mg/dl (NR 7-18) and creatinine 1.2 mg/dl (NR 0.6-1.2). 75g oral glucose tolerance test 
confirmed diabetes mellitus -fasting glucose 193 mg/dl (NR <126); two-hour value 420 
(NR<200)- and he was started on intermediate acting insulin. The combination of new-onset 
diabetes mellitus, anorexia and gross emaciation, without features of ketoacidosis, prompted 
a search for underlying malignancy. Chest x-ray was normal, but a right supra-renal mass was 
detected on sonography and confirmed on CT scan. Urinary catecholamines and 
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metanephrines were both elevated at 818 mcg/24hr (NR: <275) and 3277 (NR: 25-312), 
respectively, and serum cortisol was elevated on two consecutive days at 650 & 690 mmol/l, 
with detectable ACTH at 29 and 22 ng/l, respectively. Midnight cortisol and ACTH were 
elevated at 422 nmol/l and 28 ng/l, respectively, and there was failure of suppression on both 
ODST and LDDST, with 9am Cortisol levels 126 and 111 mmol/l, respectively (NR <50); all 
in keeping with ectopic ACTH-dependent cortisol excess (Table 3). Pituitary MRI scan was 
inconclusive, but MIBG showed increased uptake by the right adrenal tumor. 
After incremental alpha blockade he underwent laparotomy with intravenous hydrocortisone 
cover, and a 4 cm adrenal tumor was excised (histologically confirmed as 
phaeochromocytoma). Although he experienced significant hypotension post-excision, 
requiring inotropic support, thereafter he made a rapid post-operative recovery and was 
discharged on oral prednisolone 5mg daily. By 14 weeks post-operatively, he successfully 
passed the short synacthen test, with plasma cortisol physiologically suppressed <50 nmol/l 
on repeat ODST (Table 3); glycaemic control had greatly improved such that he no longer 
required insulin and he was clinically steroid-independent, having spontaneously 
discontinued Prednisolone just three weeks post-discharge. He was then lost to follow-up, as 
is typically the case for Indian patients perceiving themselves to be cured, but slides and 
paraffin-fixed blocks were retained and subsequently made available to the Newcastle 
Cellular Pathology department. Immunostaining was negative for ACTH, but 10-20% of 
tumor cells showed a strong positive reaction (cytoplasmic and granular) for CRF (Figure 
2.B). 
 
Immunohistochemistry Methods 
Immunohistochemistry was performed on a Benchmark Ultra autostainer (Ventana, Tucson, 
AZ, USA) using polyclonal anti-corticotropin releasing factor (Sigma-Aldrich, St Louis, MO, 
USA) at dilutions of 1:2000 and 1:3000 and monoclonal anti-ACTH (BioGenex, Freemont, 
CA, USA) at a dilution of 1:100. Briefly, high pH heat induced epitope retrieval was 
performed for 32 and 8 minutes, respectively, at 100OC followed by 32-minute primary 
antibody incubation. Visualisation was achieved using a Ventana OptiView DAB polymer 
detection kit (Ventana, Tucson, AZ, USA). Positive demonstration of anti-CRF was 
confirmed in human placental tissue which produced strong cytoplasmic/ membranous 
staining in the trophoblastic cells, especially syncytiotrophoblast. Positive demonstration of 
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anti-ACTH was confirmed in human pituitary which produced strong cytoplasmic staining in 
the corticotrophs. 
DISCUSSION 
Ectopic ACTH syndrome is predominantly associated with bronchial carcinoid (25% of all 
cases), with phaeochromocytoma accounting for only 3 % [3,4]. There are reports of tumors 
co-expressing ACTH and CRF, but ectopic CRF production alone is rarely reported (Table 
4.A). To our knowledge there have been only 23 convincing reports of isolated ectopic CRF 
production [5-27], among which medullary thyroid cancer was the commonest cause, while 
phaeochromocytoma accounted for only five cases (Table 4.B). The diagnostic evaluation of 
ACTH-dependent Cushing’s syndrome has been extensively reviewed, but it is worth 
restating that the key investigations in differentiating ectopic secretion from Cushing's 
disease are pituitary MRI, IPSS-with-CRF-stimulation and high-resolution cross-sectional 
imaging of the chest and abdomen. Somatostatin analog scintigraphy may be also included as 
a diagnostic step in the workup of Cushing's syndrome patients with a suspected ectopic 
ACTH production [34]. 
Pituitary ACTH-secreting corticotroph cell adenomas exist in virtually all patients with 
pituitary ACTH-hypersecretion (Cushing’s disease), though they may not always be visible 
on MRI, hence the value of IPSS, which in experienced hands has yielded a diagnostic 
accuracy approaching 100% in ACTH-dependent Cushing’s syndrome. However, false 
positive IPSS results have been reported, as has diffuse corticotroph hyperplasia following 
exploratory pituitary surgery, and both these findings are exactly what would be expected as 
a result of ectopic CRF secretion.  
To distinguish between ectopic ACTH and CRF syndromes, plasma assay and 
immunostaining of tumor samples for both ACTH and CRF would ideally be available, but 
plasma CRF levels are rarely reported in the literature, because there is typically no clinical 
imperative to do so. We were able to identify only two cases of phaeochromocytoma-
associated ACTH-driven Cushing’s syndrome, in which plasma CRF was either frankly 
elevated, or “inappropriately normal”; upper-end-of-normal in one case [12] and well-above 
the quoted reference range in the other [25]. Several reports of ectopic CRF secretion 
describe impaired cortisol-decrement following HDDST, but it is not commonly appreciated 
that this condition will necessarily result in false-positive localization of the primary tumor to 
the pituitary gland by IPSS. Herein we present three patients with phaeochromocytoma and 
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biochemical evidence of ACTH-dependent Cushing’s, among which tumor-ACTH secretion 
was only confirmed in one case; the remaining two secreting CRF -or a functionally and 
structurally closely-related peptide.  
In case 1, long term clinical symptoms raised suspicion for the presence of 
phaeochromocytoma, which was confirmed by elevated overnight urinary normetanephrines 
and metanephrines and cross-sectional imaging. Further laboratory investigations revealed 
ACTH-dependent Cushing’s. The presence of hypokalemia, older age, markedly-elevated 
circulating ACTH and the absence of definitive lesion in the pituitary MRI scan were in favor 
of ectopic ACTH; high-resolution CT chest, however, failed to show any potential culprit 
lung lesion. Therefore IPSS was undertaken, with the results suggesting a pituitary source of 
ACTH overproduction (initially interpreted as pituitary Cushing’s disease). However, as MRI 
had failed to show a convincing pituitary lesion and good medical control of Cushing’s had 
been rapidly achieved, the over-riding clinical priority was to excise the 
phaeochromocytoma.  
Following resection of the right-sided phaeochromocytoma, ACTH levels fell and cortisol 
dynamics were rapidly restored to normal, allowing early discontinuation of post-operative 
steroids; in keeping with phaeochromocytoma-associated ectopic hormone secretion. Initial 
tumor-immunostaining for ACTH was negative (Figure 2A), increasing our suspicion that 
CRF might instead be the ectopically-secreted hormone. This we later confirmed by 
immunostaining for CRF. We speculate that the rapidity of postoperative recovery of the 
HPA axis may reside in the  hypophysial corticotroph cells having been chronically-
stimulated by the ectopic CRF, rather than being suppressed by endogenous 
hypercortisolaemia.  
This index case prompted us to re-evaluate two other recent cases of phaeochromocytoma-
associated ACTH-driven Cushing’s syndrome that had both been cured following unilateral 
adrenalectomy. Although case 2 manifest a similar biochemical cure of both the hormone 
excess syndromes following (left) adrenalectomy, the HPA axis remained suppressed for 
many months afterwards and tumor-immunostaining was positive for ACTH and not for CRF 
in keeping with direct ectopic ACTH secretion by the phaeochromocytoma. Case 3 presented 
with incidental adrenal mass in the context of cachexia and new-onset diabetes mellitus. 
However, as with the index case 1, there was rapid (definitely within 14 weeks post-op, but 
most likely within 3 weeks) normalization of cortisol dynamics post-operatively. Although 
pre-operative IPSS had not been performed, tumor staining for ACTH was likewise negative 
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and staining for CRP was significantly stronger than in case 1 (Figure 2B) -again consistent 
with ectopic CRF production by the phaeochromocytoma. 
Literature review revealed 61 papers and 72 cases of phaeochromocytoma-associated 
Cushing’s syndrome (Supplementary data). In most cases pathology documented ACTH-
positive chromaffin tumor along with adrenocortical hyperplasia, while in three cases 
pathology confirmed the presence of a mixed cortico-medullary tumor in which 
corticosteroid production by the tumor per se appeared a more likely etiology than ectopic 
ACTH production [35-37]; in three other cases [38-40] the co-presence of adrenocortical 
adenoma and a phaeochromocytoma was demonstrated. IPSS was undertaken in only five 
cases and, all cases, confirmed ectopic ACTH secretion [6,41-44].  
We acknowledge the limitations of immunostaining as a surrogate for tumorous hormone 
secretion. Positive staining indicates the presence within the cells of the epitope to which the 
antibody has been raised, and it cannot be 100% inferred that the same cells had been 
secreting functionally active hormone. Indeed, Liddle, et al. demonstrated ACTH-
immunoreactivity in 8% of tumor tissue extracts from patients without the ectopic ACTH 
syndrome [28]. Conversely negative immunostaining means that the epitope has not been 
identified, which does not necessarily prove that the cells had not been secreting functionally 
active hormone. Liddle, et al. thus suggested the five criteria for confirming ectopic ACTH 
production: (1) clinical and laboratory evidence of endogenous hypercortisolemia; (2) 
positive immunostaining for ACTH in tumor extracts; (3) elevated or inappropriately normal 
plasma ACTH in the presence of hypercortisolemia; (4) evident elevated ACTH levels in the 
venous effluent from the tumor site; (5) ACTH activity fall after removal of the tumor. Only 
case 2 discussed in this paper fulfilled 4/5 criteria based on pre- and post-operative 
biochemical studies as well as pathologic confirmation.  
 
CONCLUSION  
We report three cases of phaeochromocytoma-associated ACTH-dependent Cushing’s 
syndrome, where both hormone excess syndromes resolved following unilateral 
adrenalectomy. In all three cases the source of abnormal ACTH drive was uncertain, but the 
over-riding clinical priority was to remove the phaeochromocytoma, following which 
Cushing's was demonstrably cured in all three cases. Hence, phaeochromocytoma was 
initially inferred to be the ultimate source of ACTH. However, this was confirmed only in 
case 2, where there was positive tumor-immunostaining for ACTH (negative for CRF). Cases 
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1 and 3 were similarly characterized by post-operative cure, but also exhibited relatively 
rapid restoration of normal cortisol dynamics and negative immunostaining for ACTH 
(positive for CRF). Although lack of tumour staining for ACTH in cases 1 and 3 cannot 
entirely exclude ACTH co-secretion, these cases nevertheless do appear to represent an 
extremely rare cause of ACTH-dependent Cushing’s syndrome, with ectopic CRF production 
by phaeochromocytoma driving secondary corticotroph hyperplasia. To our knowledge these 
are potentially only the 6th and 7th such reported cases. Moreover, Case 1 is the first such 
report where secondary pituitary ACTH-hypersecretion was unequivocally demonstrated with 
IPSS, initially leading to false-positive diagnosis of pituitary Cushing's disease.  
We speculate that unusually-rapid restoration of normal cortisol dynamics post-
adrenalectomy [45] for a tumor presumed to be ectopically-secreting ACTH, might instead 
indicate unrecognized ectopic CRF production. It is also conceivable that acute 
hypocortisolaemia, in relation to unrecognized co-secretion of ACTH, may underpin some 
cases of cardiovascular collapse following adrenalectomy for phaeochromocytoma. Despite 
advances in our knowledge of phaeochromocytoma genetics since the publication of previous 
reports, we were not able to identify any somatic DNA defect that might be associated with 
either ACTH- or CRF secreting phaeochromocytoma.  
 
Acknowledgements:  
The Authors wish to acknowledge Dr Srinivas Shenoy (Department of Urology) and Dr 
Shakuntala Bai (Department of Pathology), Jubilee Mission Medical College & Research 
Institute, Thrissur, Kerala, India for their assistance in the original clinical evaluation of Case 
3, and for having made slides and paraffin-fixed blocks available to us in Newcastle-upon-
Tyne.  
 
REFERENCES 
1.  Lindholm, J., Juul, S., Jorgensen, JO., et al. (2001) Incidence and late prognosis of 
Cushing syndrome: a population-based study. J Clin Endocrinol Metab, 86:117–23. 
2.  Newell-Price, J., Trainer, P., Besser, M., et al. (1998) The Diagnosis and 
Differential Diagnosis of Cushing’s Syndrome and Pseudo-Cushing’s States. Endocr Rev, 
19:647-672. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
3. Aniszewski, JP., Young WF Jr., Thompson GB., et al. (2001) Cushing 
syndrome due to ectopic adrenocorticotropic hormone secretion. World J Surg, 25(7):934-
40. 
4. Ilias, I., Torpy, DJ., Pacak, K., et al. (2005) Cushing’s Syndrome Due to Ectopic 
Corticotropin Secretion: Twenty Years’ Experience at the National Institutes of Health. J 
Clin Endocrinol Metab, 90: 4955-4962 
5. Oates, S.K., Roth, S.I., Molitch, M.E. (2000) Corticotropin-releasing hormone-
producing medullary thyroid carcinoma causing Cushing's syndrome: Clinical and 
pathological findings. Endocrine Pathology, 11:277-285.  
6. Wajchenberg, B.L., Mendonca, B., Liberman, B. (1995) Ectopic ACTH syndrome. J 
Steroid Biochem Mol Biol, 53:139-151.  
7. Eng, P.H., Tan, L.H., Wong, K.S., et al. (1999) Cushing's syndrome in a patient with 
a corticotropin-releasing hormone-producing pheochromocytoma. Endocr Pract, 5:84–87.  
8. Ruggeri, R.M., Ferrau, F., Campenni, A., et al. (2009)  Immunohistochemical 
localization and functional characterization of somatostatin receptor subtypes in a 
corticotropin releasing hormone- secreting adrenal phaeochromocytoma: review of the 
literature and report of a case. Eur J Histochem, 53:1–6.  
9. Chrisoulidou, A., Pazaitou-Panayiotou, K., Georgiou, E., et al. (2008) Ectopic 
Cushing's syndrome due to CRH secreting liver metastasis in a patient with medullary thyroid 
carcinoma. Hormones (Athens), 7:259–262. 
10. Bayraktar, F., Kebapcilar, L., Kocdor, M.A., et al. (2006) Cushing's syndrome due to 
ectopic CRH secretion by adrenal pheochromocytoma accompanied by renal infarction. Exp 
Clin Endocrinol Diabetes, 114:444–447.  
11. Saeger, W., Reincke, M., Scholz, G.H., et al. (1993) Ectopic ACTH- or CRH-
secreting tumors in Cushing's syndrome. Zentralbl Pathol, 139:157–163. 
12. Parenti, G., Nassi, R., Silvestri, S., et al. (2006) Multi-step approach in a complex 
case of Cushing's syndrome and medullary thyroid carcinoma. J Endocrinol Invest, 29:177–
181 
13. Jessop, D.S., Cunnah, D., Millar, J.G., et al. (1987) A phaeochromocytoma presenting 
with Cushing's syndrome associated with increased concentrations of circulating 
corticotrophin-releasing factor. J Endocrinol, 113:133–138.  
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
14. Auchus R.J., Mastorakos G., Friedman T.C., et al. (1994) Corticotropin-releasing 
hormone production by a small cell carcinoma in a patient with ACTH-dependent Cushing's 
syndrome. J Endocrinol Invest, 17:447–452.  
15. Kristiansen M.T., Rasmussen L.M., Olsen N., et al. (2002) Ectopic ACTH syndrome: 
discrepancy between somatostatin receptor status in vivo and ex vivo, and between 
immunostaining and gene transcription for POMC and CRH. Horm Res, 57:200–204 
16. Smallridge, R.C., Bourne, K., Pearson, B.W., et al. (2003) Cushing's syndrome due to 
medullary thyroid carcinoma: diagnosis by proopiomelanocortin messenger ribonucleic acid 
in situ hybridization. J Clin Endocrinol Metab, 88:4565–4568.  
17. Shahani, S.,  Nudelman, R.J.,  Nalini, R., et al. (2010) Ectopic corticotrophin-
releasing hormone (CRH) syndrome from metastatic small cell carcinoma: a case report and 
review of the literature.  Diagn Pathol, 5: 56.  
18. Schalin-Jäntti, C., Asa, S.L., Arola, J., et al. (2013) Recurrent acute-onset Cushing's 
syndrome 6 years after removal of a thymic neuroendocrine carcinoma: from ectopic ACTH 
to CRH. Endocr Pathol, 24:25-29.  
19. Wang, J., Zhang, G. (2008) Paraneoplastic Cushing syndrome because of 
corticotrophin-releasing hormone-secreting Wilms' tumor. J Pediatr Surg, 43:2099-101.  
20. Mondello, S., Fodale, V., Cannavò, S., et al.  (2008) Hypophosphatemia as unusual 
cause of ARDS in Cushing's syndrome secondary to ectopic CRH production. A case report. 
ScientificWorld Journal, 8:138-44 
21. Zangeneh, F., Young, W.F Jr., Lloyd, R.V., et al. (2003) Cushing's syndrome due to 
ectopic production of corticotropin-releasing hormone in an infant with 
ganglioneuroblastoma. Endocr Pract, 9:394-9. 
22. Pecori-Giraldi, F., Terreni, M.R., Andreotti, C., et al. (2003) Meningioma presenting 
with Cushing's syndrome: an unusual clinical presentation. Ann Neurol, 53:138-42. 
23. Boon, E.S., Leers, M.P., Tjwa, M.K. (1994) Ectopic Cushing's syndrome in a patient 
with squamous cell carcinoma of the lung due to CRF-like production. Monaldi Arch Chest 
Dis, 49:19-21. 
24. Preeyasombat, C., Sirikulchayanonta, V., Mahachokelertwattana, P et al. (1992) 
Cushing's syndrome caused by Ewing's sarcoma secreting corticotropin releasing factor-like 
peptide. Am J Dis Child, 146:1103-5. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
25. Schteingart, D.E., Lloyd, R.V., Akil, H., et al. (1986) Cushing's syndrome secondary 
to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion. J Clin Endocrinol 
Metab, 63:770-5. 
26. Belsky, J.L., Cuello, B., Swanson, L.W., Simmons, D.M., et al. (1985) Cushing's 
syndrome due to ectopic production of corticotropin-releasing factor. J Clin Endocrinol 
Metab, 60:496-500. 
27. Carey, R.M., Varma, S.K., Drake, C.R Jr., et al. (1984) Ectopic secretion of 
corticotropin-releasing factor as a cause of Cushing's syndrome. A clinical, morphologic, and 
biochemical study. N Engl J Med, 311:13-20. 
28. Ghander, C., Tenenbaum, F., Tissier, F., et al. (2012) When adrenal Cushing's and 
phaeochromocytoma meet. Lancet, 10;380(9854):1683 
29. O'Brien, T., Young, W.F Jr., Davila, D.G., et al. (1992) Cushing's syndrome 
associated with ectopic production of corticotrophin-releasing hormone, corticotrophin and 
vasopressin by a phaeochromocytoma. Clin Endocrinol (Oxf), 37(5):460-7. 
30. Salgado, L.R., Fragoso, M.C., Knoepfelmacher M., et al. (2006) Ectopic ACTH 
syndrome: our experience with 25 cases. Eur J Endocrinol, 155:725-33. 
31. Terzolo, M., Alì, A., Pia, A., et al. (1994)  Cyclic Cushing's syndrome due to ectopic 
ACTH secretion by an adrenal pheochromocytoma. J Endocrinol Invest, 17:869-74 
32. Berr, C.M., Di Dalmazi, G., Osswald, A., et al. (2015) Time to recovery of adrenal 
function after curative surgery for Cushing’s syndrome depends on etiology. J  Endocrinol 
Metab, 29:2014-3632. 
33. van Dam P.S., van Gils A., Canninga-van Dijk MR., et al. (2002) Sequential 
ACTH and catecholamine secretion in a phaeochromocytoma. Eur J Endocrinol, 
147(2):201-6. 
34. de Herder, W.W., Krenning, E.P., Malchoff, C.D., , et al. (1994) Somatostatin 
receptor scintigraphy: its value in tumor localization in patients with Cushing's syndrome 
caused by ectopic corticotropin or corticotropin-releasing hormone secretion. Am J Med. 
Apr, 96(4):305-12. 
35. Howlett T.A., Drury PL., Perry L., et al. (1986) Diagnosis and management of 
ACTH-dependent Cushing’s syndrome: comparison of the features in ectopic and pituitary 
ACTH production. Clinical Endocrinology, 24:699-713. 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
36. Shepherd, F.A., Laskey, J., Evans, W.K., et al. (1992) Cushing’s syndrome associated 
with ectopic corticotropin production and small-cell lung cancer. Journal of Clinical 
Oncology, 10:21–27. 
37. Mendonça, B.B., Madureira, G., Bloise, W., et al. (1989) Cushing syndrome due to 
ectopic ACTH secretion. Revista Paulista Medicina, 107:29–36. 
38. Pass, H.I., Doppman, J.L., Nieman, L., et al. (1990) Management of the ectopic 
ACTH syndrome due to thoracic carcinoids. Annals of Thoracic Surgery, 50:52–57. 
39. Liddle, G.W., Nicholson, W.E., Island, D.P., et al. (1969) Clinical and laboratory 
studies of ectopic humoral syndromes. Recent Prog Horm Res, 25:283. 
40. Akai, H., Sanoyama, K., Namai, K., et al. (1993) A case of adrenal mixed tumor of 
pheochromocytoma and adrenocortical adenoma presenting diabetes mellitus and 
hypertension. Nihon Naibunpi Gakkai Zasshi, 69:659-69.  
41. Dykes, M.H. (1969) Adrenalectomy for Cushing's syndrome--paroxysmal tachycardia 
and a unique tumor. Anesthesiology, 30:574-6 
42. Mathison, D.A., Waterhouse, C.A. (1969) Cushing's syndrome with hypertensive 
crisis and mixed adrenal cortical adenoma-pheochromocytoma (corticomedullary adenoma). 
Am J Med, 47:635. 
43. Bronshteĭn, M.E., Tsitsiashvili, B.Sh., Kolesnikova, G.S., et al. (1989) Cushing's 
syndrome in unilateral diffuse-nodular hyperplasia of the adrenal cortex with a 
corticosteroma and in combination with a pheochromocytoma. Probl Endokrinol (Mosk), 
35:46-50. 
44. Cope, O., Labbe, J.P., Raker, J.W., et al. (1952) Pheochromocytoma and adrenal 
cortical adenoma; report of a case with both tumors and discussion of their relation. J Clin 
Endocrinol Metab, 12:875-80. 
45. Ilias I., Torpy D.J., Pacak K., et al. (2005) Cushing's syndrome due to ectopic 
corticotropin secretion: twenty years' experience at the National Institutes of Health. J Clin 
Endocrinol Metab, 90(8):4955-62. 
 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
LEGENDS TO FIGURES AND TABLES 
Figure 1 
Case 1: Contrast-enhanced axial CT image showing poorly-enhancing, low-attenuation 3cm 
right adrenal mass (thin blue arrow) and a bulky left adrenal gland (bold blue arrow).  
 
Figure 2 
    ACTH and CRF immunostaining: 
(A) Case 1: Negative tumor ACTH-staining, with some positivity in the adjacent adrenal cortex  
(B) Case 3: CRF-positive cells in peripheral areas of the tumour 
 
 
Table 1 
Cases 1 and 2:  
Catecholamine dynamics pre- and post- adrenalectomy  
 
 
 
Table 2 
Case 1: 
Inferior petrosal sinus sampling with CRF infusion 
 
 
 
Table 3 
Case 3:  
Cortisol and catecholamine dynamics pre- and (14 weeks) post-right adrenalectomy 
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Table 4 
   (A) Tumors causing ectopic ACTH Cushing syndrome 
   (B) Phaeochromocytoma as source of ectopic CRF production  
 
Supplementary data: 
Cushing syndrome associated with Phaeochromocytoma 
 
 
 
 
 
Overnight urine 
μmol/mmol
Metanephrine/ 
Creatinine ratio 
Normetanephrine/ 
Creatinine ratio 
NR: <0.30 <0.35 
Case 1 Case 2 Case 1 Case 2 
pre-op:
4.0 
2.0 
1.5 
1.5 
0.50 
0.42 
9.2 
8.9 
8.6 
5.8 
0.38 
0.39 
post-op:
0.04 
0.02 
0.05 
0.06 
0.23 
0.19 
0.33 
0.19 
Plasma pmol/l Metanephrines Normetanephrines 
NR: <600 <1000 
Case 1 Case 2 Case 1 Case 2 
pre-op: 460 821 1730 1192 
post-op: 56 <50 108 95 
 
 
 
 
Table 1 
Cases 1 and 2:    
Catecholamine dynamics pre- and post- adrenalectomy 
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Table 2 (Case 1): 
IPSS with CRF infusion 
Time post-CRF infusion-start 
mins 
ACTH ng/l 
Right IPS Left IPS peripheral high IVC low IVC 
0 107 20 20 27 27 
2 439 716 20 
 
IPS = inferior petrosal sinus 
IVC = inferior vena cava
5 363 350 13 
10 169 251 29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3 
Case 3: Endocrine lab results pre- and   
(14 weeks) post-right adrenalectomy 
 
Pre-op Post-op NR 
Cortisol nmol/l 9am 650 & 690 48 200-600 
midnight 422 - <50 
1mg overnight DST 126 43 <50 
Low-dose DST 111 - <50 
ACTH ng/l 9am 29 & 22 14 <47 
midnight 20 <5 <5 
Urine: mcg/24hr Catecholamines 818 - <275 
Metanephrines 3277 - <312 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
 
Table 4 
A. Tumors causing ectopic ACTH Cushing syndrome 
ACTH-secreting [28-33]  CRF-secreting [5-27] 
Small cell carcinoma (esp. lung) 
Pancreatic islet cell tumor 
Neuroendocrine tumor (lung, thymus, gut, pancreas, ovary) 
Medullary thyroid cancer 
Phaeochromocytoma 
 
Prostate adenocarcinoma 
Choristoma / Gangliocytoma 
Wilms tumor 
Ganglioneuroblastoma 
Meningioma 
Ewing sarcoma 
B. Phaeochromocytoma as source of ectopic CRF production 
 tumor staining for: serum level: 
Investigators: ACTH CRF ACTH CRF 
Lois, et al. [Cases 1 
and 3 in this mss] 
negative positive increased - 
Bayraktar, et al. [10]  negative positive increased - 
Eng, et al. [7]  negative positive increased - 
Jessop, et al.  13]  negative positive increased increased  
Mondello, et al. [20]  - positive increased - 
Ruggeri, et al. [8]  negative positive increased - 
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